Zepbound Side Effects: What the Trials Recorded, What Is Common and What Needs a Call to Your Doctor

The pharmacist slid the box across the counter and asked a question she now asks a dozen times a week: “Did anyone talk to you about the nausea?” The woman collecting her first Zepbound prescription nodded, then admitted she had mostly read about it on social media, where one person swears the drug ruined her stomach and the next says she barely noticed a thing.

That gap between anecdote and evidence is why zepbound side effects are climbing search charts again. As of June 2025, two developments have pushed the topic back into the news: the first large head-to-head trial comparing tirzepatide with semaglutide was published in May, and the medicine picked up a second approved use, for obstructive sleep apnea in adults with obesity, in December 2024. More people are being prescribed it, and more are asking what their bodies should expect.

The honest answer is more reassuring than the horror stories and more cautious than the hype. The trials kept careful count. This article walks through what they recorded.

What changed recently with Zepbound

Zepbound is the brand name for tirzepatide when it is prescribed for weight management; the same molecule is sold as Mounjaro for type 2 diabetes. It was first approved by the US Food and Drug Administration in November 2023 for adults with obesity, or with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.

In December 2024 the FDA added moderate-to-severe obstructive sleep apnea in adults with obesity as a second approved use, making it the first medicine cleared for that condition. Obstructive sleep apnea is a disorder in which the upper airway repeatedly narrows or closes during sleep, interrupting breathing. The MedlinePlus drug entry and the Mayo Clinic monograph on tirzepatide have both been updated to reflect the broader indication.

Then, in May 2025, results of a randomized trial directly comparing tirzepatide with semaglutide (the active ingredient in Wegovy and Ozempic) in adults with obesity appeared in the New England Journal of Medicine. It was designed to compare weight change, but because both groups were followed for 72 weeks, it also produced the cleanest side-by-side safety data the class has had. Gastrointestinal complaints were the most frequent adverse events in both arms and occurred at broadly similar rates.

Why does this matter for side effects specifically? Two reasons. A wider indication means people with sleep apnea, who often have other conditions and take other medicines, are now candidates, and their questions differ from those of someone whose only concern is weight. And a head-to-head trial finally gives clinicians something better than cross-trial guesswork when a patient asks whether one drug is gentler than the other.

The freshest evidence, in short, has not uncovered new dangers. It has sharpened the picture of the ones already known.

What is Zepbound and how does tirzepatide work?

Tirzepatide is a once-weekly injection that mimics two gut hormones at once. GLP-1 (glucagon-like peptide-1) is released after eating and tells the pancreas to release insulin, slows the stomach’s emptying and signals fullness to the brain. GIP (glucose-dependent insulinotropic polypeptide) is a second meal-triggered hormone that also nudges insulin release and appears to influence how fat tissue handles energy. Because tirzepatide activates both receptors, it is described as a dual agonist; an agonist is simply a substance that switches a receptor on.

Most of the everyday side effects flow directly from that mechanism. A stomach that empties more slowly feels full longer, which is the intended effect, but the same delay can produce nausea, bloating, belching and reflux. Slower transit through the bowel can mean constipation for one person and, paradoxically, diarrhea for another as the gut adjusts. Eating less can bring fatigue in the first weeks, and rapid weight change itself has knock-on effects that are easy to blame on the drug alone.

The medicine reaches steady levels in the body over roughly four to five weeks and has a half-life of about five days, which is why one injection a week is enough. Half-life is the time it takes for half of a drug to leave the bloodstream. That long tail also explains why side effects do not vanish the day after a missed dose, and why a clinician will usually advise waiting things out rather than stopping abruptly.

Dosing is individualized. The prescriber starts low and steps up gradually over several months, partly because a slower climb gives the gut time to adapt. Exact amounts and timing are decided in the consulting room, not here.

Zepbound side effects: what the SURMOUNT trials recorded

The pivotal evidence comes from the SURMOUNT program, a series of randomized, placebo-controlled trials in adults with obesity or overweight. SURMOUNT-1, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults without diabetes and followed them for 72 weeks across three dose levels and placebo. Randomized means participants were assigned by chance; placebo-controlled means some received an inactive injection so investigators could separate drug effects from coincidence.

Here is how the most common adverse events lined up. Percentages are ranges across the three tirzepatide groups, rounded.

Side effect	Tirzepatide groups	Placebo	Typical pattern
Nausea	25–33%	10%	Peaks after dose increases, then fades
Diarrhea	19–23%	7%	Intermittent, mostly mild
Constipation	12–17%	6%	Often persists longer than nausea
Vomiting	8–12%	2%	Usually occasional, not daily
Indigestion	9–10%	4%	Fullness, belching, reflux
Fatigue	5–7%	3%	Early weeks, linked to lower intake
Hair loss	5–6%	1%	Diffuse shedding after months of weight loss
Injection-site reaction	3–4%	<1%	Redness, itch, small lump

Two figures deserve as much attention as the table. First, most gastrointestinal events were graded mild or moderate and were clustered around the periods when the dose was increased. Second, between roughly 4% and 7% of participants on tirzepatide stopped the trial because of adverse events, compared with about 3% on placebo. Put another way, well over nine in ten people who started stayed on it for the full 72 weeks.

Serious adverse events were reported at similar rates in the tirzepatide and placebo arms, and gallbladder-related events, while more frequent with the drug, remained below 1% of participants.

What the evidence actually says, and how strong it is

Not every claim about tirzepatide side effects rests on the same footing, so it helps to sort them by evidence grade.

Strong evidence (randomized controlled trials). The gastrointestinal profile is about as well established as drug safety gets. Several thousand participants across the SURMOUNT trials, plus the SURPASS diabetes program using the same molecule, consistently show nausea, diarrhea, constipation and vomiting as the leading complaints, at rates two to three times those of placebo. The hair-loss and fatigue signals, though smaller, also come from randomized data. The 2025 head-to-head trial with semaglutide adds a direct comparison rather than an inference.

Moderate evidence (trial signals plus class data). Gallbladder disease and pancreatitis appear in the prescribing information because they were observed in trials and have been reported with related GLP-1 medicines for over a decade. Their rarity means individual trials could not measure them precisely, so the estimates carry wider uncertainty. Acute kidney injury has been reported mostly in people who became dehydrated from vomiting or diarrhea, which is a mechanism rather than a mystery.

Limited evidence (observational reports and expert opinion). Questions about mood changes, muscle loss and effects after five or more years of use rely largely on observational data, meaning researchers looked at outcomes in people who happened to be taking the drug rather than assigning it by chance. Observational studies can flag associations but cannot prove cause. Regulators in the US and Europe reviewed reports of suicidal thoughts in GLP-1 users and, as of their most recent statements, did not find evidence of a causal link, while asking prescribers to keep monitoring.

Animal data only. The boxed warning about thyroid C-cell tumors comes from rodent studies. Whether it applies to humans is unknown, which is why people with certain thyroid histories are advised against the drug as a precaution rather than because harm has been shown.

How long do Zepbound side effects last?

Ask ten people this and you may hear ten answers, but the trial records reveal a pattern. Nausea tends to arrive within the first one or two days after an injection, is most noticeable in the first few weeks on a new dose level, and for most participants settled within a few weeks as the gut adapted. Because the prescriber steps the dose up gradually over months, some people describe a rhythm: a rough week after each increase, then calm.

Constipation behaves differently. It is less dramatic than nausea but more stubborn, and in trials it was among the complaints most likely to persist beyond the adjustment window. Slower gut movement is a lasting feature of the drug’s action, so this is one effect people often manage rather than outgrow.

Fatigue and lightheadedness usually track eating and drinking. When appetite drops sharply, some people simply consume too little fluid and too few calories in the early weeks; energy typically returns once intake stabilizes at a sustainable level.

Hair shedding follows a delayed timetable. Telogen effluvium, the medical name for diffuse shedding triggered by a physical stress such as rapid weight loss, typically appears two to four months after the trigger and resolves over several months once weight stabilizes. It shows up in trials of every effective weight-loss method, not only this one.

Injection-site reactions, when they occur, generally last a day or two.

Because tirzepatide’s half-life is about five days, side effects do not switch off the moment a dose is skipped; the drug lingers for two to three weeks. A clinician who wants to ease persistent symptoms has options, from slowing the increase to holding at a lower level, but those adjustments belong to the prescriber, not to a self-directed change.

Zepbound nausea, constipation and diarrhea: why the gut takes the hit

The digestive system is where tirzepatide does much of its work, so it is also where most complaints originate. Understanding the mechanics makes the symptoms less alarming.

Nausea is largely a consequence of delayed gastric emptying. Food sits in the stomach longer, stretch receptors in the stomach wall stay activated, and the brain interprets that signal as fullness edging into queasiness. Large, fatty or very sugary meals amplify the effect because they empty slowly even in an untreated stomach. Trial participants and clinicians consistently report that smaller portions, eating slowly and stopping at the first hint of fullness make a noticeable difference. Strong food smells and lying down soon after eating tend to make matters worse.

Reflux and belching share the same root. A fuller stomach for longer means more opportunity for acid to travel upward, especially at night.

Constipation results from slower transit through the entire digestive tract combined with two changes that often accompany appetite loss: less fiber and less fluid. Cleveland Clinic and NHS guidance on GLP-1 class medicines emphasize hydration and fiber as first-line measures, with a clinician’s advice before adding any laxative product.

Diarrhea seems contradictory, yet roughly one in five trial participants reported it. It is generally intermittent rather than daily and may reflect changes in gut hormone signaling, bile flow and the gut’s bacterial population as eating patterns shift.

Vomiting was reported by around one in ten participants and was rarely frequent. The important line is between occasional vomiting after an unwise meal and repeated vomiting that prevents keeping fluids down, because the second can lead to dehydration and, in reported cases, kidney injury. That threshold is covered in the doctor section later, but it bears remembering here: the gut effects are usually a nuisance, and only occasionally a warning.

Do Zepbound side effects change by dose?

The short answer from the trials is yes, modestly, and mostly in the direction people would guess. In SURMOUNT-1, nausea, diarrhea and vomiting were each reported a few percentage points more often in the highest-dose group than in the lowest, and discontinuation for adverse events followed the same slope. The gap was smaller than many expect, though: nausea rose from roughly a quarter of participants at the lowest studied level to about a third at the highest.

What matters more than the maintenance dose reached is the moment of change. Adverse events clustered in the weeks immediately after each step up, then declined. That is the whole rationale for gradual increases: the gut is given time to adapt before being asked to adapt again. It also explains a common frustration, in which someone who felt fine for a month suddenly feels queasy again after a routine increase. Nothing has gone wrong; the pattern is repeating.

Individual variation swamps the dose effect. Some people on the highest studied dose reported no gastrointestinal symptoms at all, while a minority struggled on the lowest. Predictors are not well established, though those who have had motion sickness, reflux or a history of gastroparesis (a condition in which the stomach empties abnormally slowly) may be more susceptible and should tell their prescriber.

The prescribing information gives clinicians flexibility. If symptoms are troublesome, the increase can be delayed or the dose held at a tolerated level for longer, and trial data suggest that people who stayed at intermediate levels still saw substantial benefit. Those judgments rest on the individual’s response, other medicines and goals, and they are made by the treating clinician. Adjusting a dose without that conversation is one of the things the next sections advise against.

Hair loss, fatigue and “Zepbound face”: the less-discussed tirzepatide side effects

Scroll long enough and you will encounter three complaints that rarely lead the official list but dominate the comment threads.

Hair thinning. About 5% to 6% of tirzepatide participants in SURMOUNT-1 reported hair loss, against roughly 1% on placebo. The mechanism is almost certainly telogen effluvium, the shedding that follows rapid weight loss, major illness, childbirth or surgery. Hair follicles shift into a resting phase in response to physiological stress and release their hairs a few months later. The same phenomenon is documented after bariatric surgery and very-low-calorie diets. Shedding is diffuse rather than patchy, and it typically reverses once weight stabilizes. Because it appears months after starting, people often do not connect it to the drug until they read about it.

Fatigue. Reported by 5% to 7% of participants, fatigue in the early weeks usually reflects a steep drop in calorie and fluid intake before the body recalibrates. Persistent exhaustion, especially with dizziness or a racing heart, deserves a check for dehydration or, in people also taking insulin or sulfonylureas, low blood sugar.

Facial changes. The viral phrase describes a gaunt or aged look in people who lose weight quickly. Harvard Health has addressed this directly: the drug does not act on facial tissue. Fat loss from the cheeks and temples occurs with any rapid weight loss, and skin that has stretched over years does not always retract quickly. It is cosmetic rather than medical, more visible in older adults, and generally less pronounced when weight comes off gradually.

Other items in the trial records worth knowing about include dizziness, mild heart-rate increases of a few beats per minute, burping, and occasional altered taste. Each affected small minorities and rarely led anyone to stop.

Serious but uncommon: pancreatitis, gallbladder disease and kidney injury

Three warnings sit in the prescribing information because they are potentially serious, not because they are frequent. Knowing what they look like turns a vague worry into a specific checklist.

Pancreatitis is inflammation of the pancreas, the organ behind the stomach that produces insulin and digestive enzymes. Cases were reported in tirzepatide trials and across the GLP-1 class, though large analyses have not established how much of the risk is attributable to the drugs versus the obesity and gallstones that often accompany them. The signal symptom is severe, persistent pain in the upper abdomen that may bore through to the back, often with vomiting. It is different in kind from ordinary drug-related nausea: it does not come and go with meals, and it does not ease when the stomach is empty. Anyone with a history of pancreatitis should make sure the prescriber knows.

Gallbladder disease, including gallstones and inflammation of the gallbladder, was reported in under 1% of trial participants on tirzepatide, more than on placebo. Rapid weight loss by any means raises gallstone risk because the liver releases more cholesterol into bile while the gallbladder empties less often. Pain under the right ribs, especially after fatty meals, along with fever or yellowing of the skin or eyes, is the pattern to watch.

Acute kidney injury has been reported mostly in people who became dehydrated from repeated vomiting or diarrhea. The kidneys depend on adequate fluid volume; when it falls sharply, their filtering slows. Reduced urination, unusual drowsiness and confusion are the warning signs. People with pre-existing kidney disease are at greater risk and are usually monitored more closely.

Severe allergic reactions, with facial swelling or difficulty breathing, are rare but require emergency care. Each of these scenarios is spelled out again in the section on when to see a doctor.

The thyroid warning: what the boxed label means and does not mean

Zepbound carries the FDA’s most prominent caution, a boxed warning, about thyroid C-cell tumors. Reading it cold can be frightening, so it is worth unpacking precisely.

In studies of rats and mice, tirzepatide and other GLP-1 receptor agonists caused tumors of the thyroid’s C-cells, the cells that produce the hormone calcitonin. Rodent thyroids carry far more GLP-1 receptors than human thyroids do, and rodents in these studies received high, prolonged exposure. Whether the finding translates to people is unknown. More than fifteen years of human use of GLP-1 medicines have not produced a confirmed causal link to medullary thyroid carcinoma, the human cancer arising from C-cells, and large observational analyses have been reassuring, though observational data cannot fully exclude a small risk.

Regulators treat the uncertainty with precaution. The medicine is not recommended for anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, an inherited condition that predisposes to that cancer. Routine calcitonin blood tests or thyroid ultrasounds are not recommended for everyone, because they generate false alarms without proven benefit.

Symptoms that warrant evaluation, according to the prescribing information, are a lump or swelling in the neck, hoarseness that does not resolve, difficulty swallowing and shortness of breath. Most such symptoms turn out to have ordinary causes, but they should be assessed rather than watched.

Where does this leave a person weighing the warning? The evidence grade is animal data plus reassuring but imperfect human observation. A clinician who knows the individual’s family history is the right person to interpret it. What the label does not say is that the drug has been shown to cause thyroid cancer in people; it says the question has not been closed.

Zepbound long-term side effects: what is known and what is not

The longest randomized data for tirzepatide in weight management currently run to about three years, from a trial in adults with prediabetes that followed participants for 176 weeks. Over that span the side-effect profile did not change character: gastrointestinal effects remained the most common, concentrated early, with no new categories of harm emerging. That is genuinely reassuring, but three years is not a lifetime, and the trials were not designed to detect very rare events.

Several long-term questions remain open and honest clinicians say so.

Lean mass. Any substantial weight loss includes some muscle. Body-composition sub-studies in the trials suggest roughly a quarter of weight lost was lean tissue, a proportion similar to diet-induced loss. Whether that matters for strength or bone in older adults over many years is unresolved; resistance exercise and adequate protein are widely recommended on physiological grounds.

Weight regain after stopping. A randomized withdrawal study found that participants switched to placebo regained a substantial share of lost weight within a year, while those who continued largely maintained it. This is not a side effect in the usual sense, but it shapes how long people stay on the drug, and duration is what long-term safety depends on.

Mood. Regulators have reviewed reports of suicidal thoughts across the GLP-1 class and have not found a causal link, while asking prescribers to monitor people with a history of depression.

Eye disease in diabetes. Rapid improvement in blood sugar can transiently worsen diabetic retinopathy; this is relevant to people with diabetes and warrants eye checks.

The medicine’s class cousin semaglutide has cardiovascular-outcome data showing benefit; tirzepatide’s own large cardiovascular trial in obesity is ongoing. Until it reports, heart effects rest on class evidence and biomarkers rather than hard outcomes.

What not to do when taking Zepbound

People searching this phrase usually want a practical list, and the prescribing information and mainstream guidance supply one. Every item here is a prompt for a conversation with the prescriber, not a substitute for it.

• Do not adjust the dose on your own. Skipping ahead to speed results or halving it to dodge nausea both undermine the gradual-adaptation logic and, in the first case, raise the chance of vomiting and dehydration.
• Do not ignore fluids. Reduced thirst often accompanies reduced appetite. Dehydration is the common thread behind the kidney injuries reported with this class.
• Do not combine with insulin or sulfonylureas without a plan. Tirzepatide does not cause low blood sugar on its own, but alongside those medicines it can. Clinicians typically review the other drugs before starting.
• Do not assume oral medicines are unaffected. Slower stomach emptying can change how quickly pills are absorbed. Oral contraceptives are the specific example in the label, with a recommendation to discuss backup methods around starting and dose increases.
• Do not go into surgery without telling the anesthesia team. Food may remain in the stomach longer than expected, and anesthesiologists have published guidance on this. Whether to pause the medicine beforehand is their call.
• Do not use it during pregnancy or while planning one. Animal data suggest fetal risk, and the medicine is generally stopped before conception on the prescriber’s advice.
• Do not source it outside a legitimate prescription. Compounded and unregulated copies are not the FDA-approved product, have not been tested for purity or potency, and are not appropriate for self-use.

Alcohol is not formally contraindicated, but it irritates the stomach and adds calories without nutrition, so many clinicians suggest minimizing it, particularly in the early weeks.

Common myths about Zepbound side effects

Viral claims travel faster than trial appendices. These are the ones a clinician hears most often, with what the evidence supports.

“Everyone gets terrible nausea.” Roughly two-thirds to three-quarters of trial participants did not report nausea at all, and among those who did, most rated it mild or moderate. Severe nausea leading to discontinuation affected a small minority.

“It paralyzes your stomach.” Delayed gastric emptying is the mechanism, and it is dose-related and reversible. Gastroparesis, a persistent disorder of stomach emptying, has been reported rarely and mostly in people with pre-existing risk such as long-standing diabetes. The trials did not show a wave of permanent stomach dysfunction.

“Zepbound face is a side effect of the drug.” The change is a consequence of losing facial fat quickly and occurs with any rapid weight loss. The molecule has no action on facial skin or fat specifically.

“It causes thyroid cancer.” The warning stems from rodent studies. Human evidence over more than a decade of GLP-1 use has not confirmed a link, though the question is not considered closed.

“It causes depression and suicidal thoughts.” Regulatory reviews in the US and Europe found no evidence of causation. Monitoring continues, and anyone noticing mood changes should report them.

“Side effects mean it is working.” Weight loss in the trials did not depend on experiencing nausea; people without gastrointestinal symptoms lost weight too. Symptoms are a signal of adjustment, not a gauge of efficacy.

“Ozempic is safer.” Semaglutide and tirzepatide share a class and a side-effect profile. The 2025 head-to-head trial showed gastrointestinal events at similar rates in both arms. Neither has been shown to be meaningfully safer than the other; the choice depends on the individual’s history and goals.

When to see a doctor about Zepbound side effects

Most people on tirzepatide will never need this section. The ones who do should not hesitate. The line to remember is that ordinary side effects are unpleasant but bounded, while warning signs are severe, persistent or new in kind.

Seek emergency care immediately for:

• Swelling of the face, lips, tongue or throat, difficulty breathing, or a widespread rash, which can signal a serious allergic reaction.
• Severe, unrelenting pain in the upper abdomen, especially if it radiates to the back and comes with vomiting, which may indicate pancreatitis.
• Confusion, extreme drowsiness or fainting, which can accompany severe dehydration or, in people also taking insulin or a sulfonylurea, dangerously low blood sugar.

Contact the prescribing clinician promptly (same day or next) for:

• Vomiting or diarrhea that prevents keeping fluids down for more than about a day, or noticeably reduced urination.
• Pain under the right ribs, fever, or yellowing of the skin or eyes, which can point to gallbladder trouble.
• A lump or swelling in the neck, persistent hoarseness or trouble swallowing.
• Sudden changes in vision, particularly in people with diabetes.
• New or worsening low mood, or any thoughts of self-harm.
• A rapid or pounding heartbeat that does not settle.

Mention at the next scheduled visit: nausea or constipation that has not eased after several weeks on the same dose, hair shedding, fatigue that limits daily activity, injection-site reactions that recur, or any concern that makes you consider stopping.

Do not stop, skip or change the dose of Zepbound, or of any other prescribed medicine, without speaking to the clinician who prescribed it. Every adjustment described in this article, from slowing the increase to pausing before surgery, is a decision for the treating clinician who knows the whole picture.

Frequently asked questions

Is Ozempic safer than Zepbound?

No trial has shown either medicine to be safer overall. Ozempic contains semaglutide and is approved for type 2 diabetes, while Zepbound contains tirzepatide and is approved for weight management and obstructive sleep apnea. Both belong to the GLP-1 class and share the same leading side effects. A 2025 randomized comparison found gastrointestinal adverse events at similar rates in both groups. Which is appropriate depends on individual history, other medicines and goals, a judgment for the prescribing clinician.

What not to do when taking Zepbound?

Do not change the dose without the prescriber’s guidance, let yourself become dehydrated, combine it with insulin or sulfonylureas without a monitoring plan, or go into surgery without telling the anesthesia team. Oral contraceptives may be absorbed differently, so backup methods are discussed around starting and dose increases. It is not used in pregnancy. Compounded or unregulated copies are not the approved product and are not appropriate for self-use.

How much weight can you lose on Zepbound in 3 months?

Three-month results vary widely and the pivotal trials were designed around 72 weeks, not 12. During the first months the dose is still being stepped up gradually, so early weight change is typically modest compared with later averages. Trial averages describe groups, not individuals, and depend on diet, activity and adherence. Anyone tracking progress should set expectations with their clinician rather than against social media timelines.

Does Zepbound have any long-term side effects?

Randomized data currently extend to about three years, and over that span the side-effect profile stayed consistent: gastrointestinal effects early, no new categories of harm emerging. Open questions include the long-term significance of lean-mass loss, weight regain after stopping, and rare events too uncommon for trials to measure precisely. The thyroid warning remains based on animal data. A large cardiovascular-outcome trial for tirzepatide in obesity is still ongoing.

How long do Zepbound side effects last after each dose increase?

Nausea and related symptoms usually peak in the first one to two days after an injection and are most noticeable during the first few weeks on a new dose level, then settle as the gut adapts. Constipation often lingers longer. Because the drug’s half-life is about five days, symptoms do not vanish immediately if a dose is missed. Persistent symptoms beyond several weeks are worth raising with the prescriber.

What are the most common tirzepatide side effects?

Nausea, diarrhea, constipation, vomiting, indigestion and decreased appetite lead the list in every trial. Smaller minorities reported fatigue, hair thinning, dizziness, burping, injection-site reactions and a slight rise in resting heart rate. Most were graded mild or moderate and were concentrated around dose increases. Serious events such as pancreatitis, gallbladder disease and dehydration-related kidney injury are uncommon but are the reason the prescribing information carries specific warnings.

Why does Zepbound cause nausea?

Tirzepatide slows the rate at which the stomach empties, so food remains there longer and stretch receptors keep signaling fullness to the brain, which can tip into queasiness. Large, fatty or very sweet meals worsen it because they empty slowly anyway. Nausea is most common after dose increases and generally fades as the gut adjusts. Smaller portions, eating slowly and avoiding lying down after meals are the measures most often recommended.

Does Zepbound cause hair loss?

About 5% to 6% of trial participants reported hair loss, compared with roughly 1% on placebo. The likely cause is telogen effluvium, diffuse shedding triggered by the physiological stress of rapid weight loss, which is also seen after bariatric surgery and strict diets. It typically appears a few months after weight loss begins and resolves over several months once weight stabilizes. Adequate protein intake is often discussed with the clinician.

Can Zepbound cause pancreatitis or gallbladder problems?

Both have been reported and appear in the prescribing information, though each affected well under 1% of trial participants. Rapid weight loss itself raises gallstone risk, which complicates attributing cases to the drug alone. Severe, persistent upper-abdominal pain radiating to the back suggests pancreatitis; pain under the right ribs with fever or jaundice suggests gallbladder disease. Either pattern warrants prompt medical assessment rather than waiting for the next appointment.

What does the thyroid warning on Zepbound mean?

The boxed warning refers to thyroid C-cell tumors seen in rats and mice given GLP-1 receptor agonists. Rodent thyroids have far more of the relevant receptors than human thyroids, and more than a decade of human use has not confirmed a causal link, though the question is not closed. People with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome are advised against the medicine as a precaution.

References

• MedlinePlus: Tirzepatide Injection
• Cleveland Clinic: GLP-1 Agonists
• PubMed: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.